Cure My Disease

Don't miss your cure!

 Log in / Sign up

500 eye melanoma patients share their quality of life journey

NCT ID NCT05377957

Knowledge-focused Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatments—like radiation or surgery—impact quality of life over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand how eye melanoma and its treatments affect patients' daily lives and mental health.
What could go wrong
This is an observational study, not a treatment trial. It collects data but does not test any new therapy, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2019

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with uveal melanoma who will be treated with brachytherapy, proton therapy or enucleation with curative intent

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Clinical or pathological diagnosis of a melanoma of the choroid or ciliary body * No signs of metastasis after staging procedures with at least an X-thorax, blood test and an ultrasound of the liver * Treatment by brachytherapy, proton therapy or enucleation Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Uveal melanoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Patient Preference uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Uveal melanoma

Contacts and locations

Locations

  • Leiden University Medical Center

    Leiden, South Holland, 2333ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.